Deals in Depth: October 2009
Sanofi-Aventis was the standout in pharma alliances, penning three of the big deals, which together were worth over $1 billion in potential deal value. Onyx's buy of cancer and immunology biotech Proteolix topped the M&A chart at $851 million. In devices, notable was Kimberly-Clark, which followed up last month's Baylis acquisition with another in pain management--I-Flow, for $309 million, over twice that company's sales. Almost 40% of pharma financing came from Talecris' $600 million notes offering. And fundraising for the device industry was boosted by an $88 million IPO completed by AGA Medical Holdings, and a $55 million Series B from TransEnterix.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.